Orgenesis Inc. (ORGS)

Overview

Orgenesis Inc. is a biotech company with a global focus on developing advanced cell and gene therapies. Initially named Business Outsourcing Service, Inc., the company underwent a rebranding to Orgenesis Inc. in August 2011, emphasizing its pivot towards biotechnology. Since its inception in 2008, based in Germantown, Maryland, Orgenesis has dedicated itself to the innovation of healthcare through its proprietary Point of Care (POCare) platform. This platform signifies a breakthrough in the medical sector by facilitating the processing and production of cell and gene therapies directly at the point of care, utilizing automated, closed system technologies within a collaborative network. By concentrating on autologous therapies – treatments derived from an individual's own cells – Orgenesis aims to revolutionize patient-specific care with systems designed for compliant, onsite production of therapeutic solutions.

Products and Services

The core of Orgenesis's offering revolves around its Point of Care (POCare) platform, which encompasses a suite of technologies and services designed to bring cell and gene therapy production closer to the patient:

• POCare Platform: An innovative solution that integrates licensed POCare therapeutics ready for processing and production within an automated and closed technology system. This platform stands out for its ability to bring cutting-edge treatment directly to the patient's bedside, fostering a more personalized and efficient therapeutic experience.
• Closed and Automated Processing Systems: These systems are at the heart of the POCare Platform, designed uniquely for each therapy. By focusing on a closed and automated processing approach, Orgenesis ensures that the production of each autologous therapy complies with stringent regulatory standards while minimizing contamination risks. This system underscores the company's commitment to safety and quality in delivering patient-specific treatments.